MetaCap

LB Pharmaceuticals Inc (LBRX)

NASDAQ: LBRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

38.85-1.19 (-2.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LBRX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.12
52-week range
15.55 – 50.16
Day range
38.57 – 40.67
Volume / Avg
302.94K / 373.16K
Beta
—

52-week range

$15.55$50.16

LBRX stock today

On Nov 20, LBRX ended the session at $38.85, shedding $1.19 (2.97%), versus the S&P 500's 3.70% decline. At this level, LBRX sits in the middle of its 52-week range of $15.55 to $50.16: 22.5% below the high, set on Aug 25, 2026 and 149.8% above the low. LBRX is up 74.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 153.4%.

LB Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.12), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About LB Pharmaceuticals

Company profile

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Heather D. Turner Esq., J.D.
Headquarters
New York, NY
Employees
62
IPO year
2025

Financial highlights

Full financials

LB Pharmaceuticals reported a net loss of $25.2 million, compared with a loss of $63.1 million a year earlier. Diluted earnings per share came in at -$3.13.

LB Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024
Revenue——
Growth——
Net income$-25.20M$-63.10M
EPS (diluted)$-3.13$-176.15

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$58.00+49.29%

  • Strong buy 2
  • Buy 8
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $35.00High $80.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-1.79 vs $-1.61
Surprise
-11.18%

LBRX news

All LBRX news

LB Pharmaceuticals peers

Health Care sector
LBRX peer companies
CompanyPrice% ChgMarket capCompare
AVLNAvalyn Pharma Inc.28.40-1.05%$1.26Bvs LBRX
MNKDMannKind Corporation3.85-2.53%$1.24Bvs LBRX
SLNSilence Therapeutics Plc American Depository Share19.810.00%$1.23Bvs LBRX
GENBGenerate Biomedicines Inc.9.54-8.00%$1.23Bvs LBRX
OCULOcular Therapeutix Inc.5.57-4.95%$1.23Bvs LBRX
MLYSMineralys Therapeutics Inc.13.66-3.53%$1.21Bvs LBRX
INVAInnoviva Inc.18.410.00%$1.31Bvs LBRX
AMPHAmphastar Pharmaceuticals Inc.28.25+0.50%$1.20Bvs LBRX

Indexes, lists and sector

LB Pharmaceuticals stock FAQ

What is LB Pharmaceuticals's stock price today?

LBRX last traded at $38.85 as of Nov 20, 4:00 PM EST, down 2.97% on the day. Prices are delayed at least 15 minutes.

Who is LB Pharmaceuticals's CEO?

Ms. Heather D. Turner Esq., J.D. is the chief executive officer of LB Pharmaceuticals Inc, which has about 62 employees.

What is the LBRX 52-week high?

The 52-week high for LBRX is $50.16 and the 52-week low is $15.55. The stock is currently 22.5% below its high.

Compare LBRX